Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Lumakras (sotorasib) was granted accelerated approval for the treatment of advanced non-small-cell lung cancer.
Lumakras led to tumor shrinkage in 36% of NSCLC patients with KRAS G12C mutations.
The theme of this issue is the science underlying advances in cancer care and treatment.
More than 80% of lung cancer patients treated with the targeted therapy experienced remission or had stable disease.
The technology used in COVID-19 vaccines may also be used to prevent other viral infections and to treat cancer and multiple sclerosis.
Sotorasib and adagrasib target a specific cancer-causing mutation found in those with non-small-cell lung cancer and colorectal cancer.
Genomic testing can help customize treatment to target tumors.
Adagrasib targets a specific cancer-causing mutation, while VS-6766 interferes with multiple steps in a cell growth signaling pathway.
The drug also showed promise for colorectal and other cancers, but it might work better in combination regimens.
The study helps explain how cancer cells adapt and tolerate treatment and identify combination therapies to improve outcomes in people.
To take advantage of these new therapies, people must first learn whether their cancer harbors targetable mutations.
MRTX849 shrank tumors in half of lung cancer patients with a common but difficult to target mutation.
First KRAS targeted therapy shows promise for lung and colon cancer
Half of study participants treated with AMG 510 saw their tumors shrink, and only one experienced disease progression.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.